We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Inhalant Measles Vaccine Could Save Thousands of Lives

By HospiMedica International staff writers
Posted on 02 Sep 2009
A dry-powder, inhalable, needle-free vaccine has been designed for developing countries, where lack of clean water, sterile needles, and electricity for refrigeration hinder the administration of traditional liquid vaccines.

Researchers from the University of Colorado (Boulder, USA) developed the inhalable form of the vaccine using a patented process known as carbon dioxide-assisted nebulization with a bubble dryer (CAN-BD). More...
In this process, the weakened vaccine, dissolved in water or an alcohol (or both), is mixed intimately with near-critical or supercritical CO2 by pumping both fluids through a low volume tee-valve to generate microbubbles and microdroplets, which are then decompressed into a low-temperature drying chamber, where the aerosol plume dries in seconds.

The process allows the particles to be scaled in the 3-5 µm size range (suitable for lung delivery), without destroying biologic activity. The dried and micronized vaccine is maintained throughout the process at near ambient conditions, thus retaining its bioactivity. The CAN-BD process has been shown to successfully produce stabile dry powders that have passed the World Health Organization (WHO) stability test for one week at an ambient temperature of 37 oC.

The researchers are now are working on an inexpensive dry powder inhaler that would deliver measles (or alternatively influenza) vaccines to developing nations. In replacing the injection method of vaccination delivery, the new method also would help reach those who refuse inoculations because of their fear of needles. Human clinical trials are expected to begin in India in 2010, after animal safety studies are completed by the end of 2009. The researchers claim that the vaccine could be produced for about US$0.26 per dose. The study was presented at the 238th national meeting of the American Chemical Society (ACS), held during August 2009 in Washington (DC, USA).

"Childhood vaccines that can be inhaled and delivered directly to mucosal surfaces have the potential to offer significant advantages over injection,” said lead author Robert Sievers, Ph.D., of the center for pharmaceutical biotechnology. "Not only might they reduce the risk of infection from HIV, hepatitis, and other serious diseases due to unsterilized needles, they may prove more effective against disease.”

Supercritical carbon dioxide refers to carbon dioxide that is in a fluid state while also being at or above both its critical temperature and pressure. Carbon dioxide usually behaves as a gas in air at or as a solid called dry ice when frozen. If the temperature and pressure are both increased to be at or above the critical point for carbon dioxide, it can adopt properties midway between a gas and a liquid. More specifically, it behaves as a supercritical fluid above its critical temperature (31.1 °C) and critical pressure (7.39 MPa), expanding to fill its container like a gas but with a density like that of a liquid. Supercritical CO2 is becoming an important commercial and industrial solvent due to its role in chemical extraction in addition to its low toxicity and environmental impact. The relatively low temperature of the process and the stability of CO2 also allow most compounds to be extracted with little damage or denaturing.

Related Links:
University of Colorado


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.